Cardiovascular and bleeding risk of non-cardiac surgery in patients on antiplatelet therapy

Journal of Cardiology

Volumn 64, Issue 5, 2014, Pages 334-338

  Yamamoto, Kei ^a   Wada, Hiroshi ^a   Sakakura, Kenichi ^a   Ikeda, Nahoko ^a   Yamada, Yoko ^a   Katayama, Takuji ^a   Sugawara, Yoshitaka ^a   Mitsuhashi, Takeshi ^a   Ako, Junya ^a   Momomura, Shin ichi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Antiplatelet therapy; Bleeding; Heparin bridge; Non cardiac surgery; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; HEPARIN; PACLITAXEL; TICLOPIDINE; ZOTAROLIMUS; ANTITHROMBOCYTIC AGENT; MEMBRANE PROTEIN; TMEM158 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

AGED; AORTA SURGERY; ARTICLE; BARE METAL STENT; BLEEDING; COMBINATION CHEMOTHERAPY; DRUG ELUTING STENT; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD; RISK FACTOR; STENT THROMBOSIS; TREATMENT OUTCOME; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; HEMORRHAGE; MIDDLE AGED; RETROSPECTIVE STUDY; STENT; TIME;

AGED; ASPIRIN; CARDIOVASCULAR DISEASES; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE CARE; PERIOPERATIVE PERIOD; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; STENTS; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84912028481     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2014.02.027     Document Type: Article

References (16)

1. Kushner F.G., Hand M., Smith S.C., King S.B., Anderson J.L., Antman E.M., Bailey S.R., Bates E.R., Blankenship J.C., Casey D.E., Green L.A., Hochman J.S., Jacobs A.K., Krumholz H.M., Morrison D.A., et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2009, 120:2271-2306.
2. van Werkum J.W., Heestermans A.A., Zomer A.C., Kelder J.C., Suttorp M.J., Rensing B.J., Koolen J.J., Brueren B.R., Dambrink J.H., Hautvast R.W., Verheugt F.W., ten Berg J.M. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009, 53:1399-1409.
3. Ferreira-Gonzalez I., Marsal J.R., Ribera A., Permanyer-Miralda G., García-Del Blanco B., Martí G., Cascant P., Martín-Yuste V., Brugaletta S., Sabaté M., Alfonso F., Capote M.L., De La Torre J.M., Ruíz-Lera M., Sanmiguel D., et al. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation 2010, 122:1017-1025.
4. Cruden N.L., Harding S.A., Flapan A.D., Graham C., Wild S.H., Slack R., Pell J.P., Newby D.E. Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery. Circ Cardiovasc Interv 2010, 3:236-242. Scottish Coronary Revascularisation Register Steering Committee.
5. Berger P.B., Kleiman N.S., Pencina M.J., Hsieh W.H., Steinhubl S.R., Jeremias A., Sonel A., Browne K., Barseness G., Cohen D.J. Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement: results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. JACC Cardiovasc Interv 2010, 3:920-927. EVENT Investigators.
6. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine, Society for Vascular Surgery, Fleisher L.A., Beckman J.A., Brown K.A., Calkins H., Chaikof E.L., Fleischmann K.E., Freeman W.K., et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol 2009, 54:e13-e118.
7. Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.A., Steg P.G., Morel M.A., Mauri L., Vranckx P., McFadden E., Lansky A., Hamon M., Krucoff M.W., Serruys P.W., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007, 115:2344-2351.
8. Bovill E.G., Terrin M.L., Stump D.C., Berke A.D., Frederick M., Collen D., Feit F., Gore J.M., Hillis L.D., Lambrew C.T., Leiboff R., Mann K.G., Markis J.E., Pratt C.M., Sharkey S.W., et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI), phase II trial. Ann Intern Med 1991, 115:256-265.
9. Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 2010, 38(Suppl.):S1-S52. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).
10. van Kuijk J.P., Flu W.J., Schouten O., Hoeks S.E., Schenkeveld L., de Jaegere P.P., Bax J.J., van Domburg R.T., Serruys P.W., Poldermans D. Timing of noncardiac surgery after coronary artery stenting with bare metal or drug-eluting stents. Am J Cardiol 2009, 104:1229-1234.
11. Burger W., Chemnitius J.M., Kneissl G.D., Rucker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med 2005, 257:399-414.
12. Tokushige A., Shiomi H., Morimoto T., Furukawa Y., Nakagawa Y., Kadota K., Iwabuchi M., Shizuta S., Tada T., Tazaki J., Kato Y., Hayano M., Abe M., Ehara N., Inada T., et al. Incidence and outcome of surgical procedures after coronary bare-metal and drug-eluting stent implantation: a report from the CREDO-Kyoto PCI/CABG Registry Cohort-2. Circ Cardiovasc Interv 2012, 5:237-246.
13. Albaladejo P., Marret E., Samama C.M., Collet J.P., Abhay K., Loutrel O., Charbonneau H., Jaber S., Thoret S., Bosson J.L., Piriou V. Non-cardiac surgery in patients with coronary stents: the RECO study. Heart 2011, 97:1566-1572.
14. Hochholzer W., Trenk D., Fromm M.F., Valina C.M., Stratz C., Bestehorn H.P., Büttner H.J., Neumann F.J. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010, 55:2427-2434.
15. Vicenzi M.N., Meislitzer T., Heitzinger B., Halaj M., Fleisher L.A., Metzler H. Coronary artery stenting and non-cardiac surgery. Br J Anaesth 2006, 96:686-693.
16. Birnie D.H., Healey J.S., Wells G.A., Verma A., Tang A.S., Krahn A.D., Simpson C.S., Ayala-Paredes F., Coutu B., Leiria T.L., Essebag V. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013, 368:2084-2093. BRUISE CONTROL Investigators.